491 / 604
Phase II or retrospec+ve cohorts
Author; year
Design
Pts
Dose/frx
m-‐FU
Local control
2-‐years (%)
Survival
1-‐, 2-‐ years (%)
Mendez-‐
Romero 2006
Phase I/II
17
3x10-‐12.5 Gy
13 mts
86
85, 62
Rusthoven 2009 Phase I/II
47
3x12-‐20 Gy
16 mts
92
77, 30
Lee 2009
Phase I
68
6x4.6-‐10 Gy
11 mts
71 (1-‐yr)
79, 41 (3 yr.)
Goodman 2010
Phase I
19
1x18-‐30 Gy
17 mts
75
62, 49
Rule 2010
Phase I
27
3x10 Gy,
5x10 Gy,
5x12 Gy
20 mts
56
89
100
90, 50
78, 67
75, 56
Chang 2011
Retrospect
65
2-‐3x20 Gy
55
38 (2-‐yr)
77,45
Scorsei 2013
Phase II
61
3x25 Gy
12
91
83,38
Comito 2014
Phase II
42
4x12 –
3x25 Gy
24
80
80, 65
DeVin 2014
Retrospect
77
10x4-‐5 Gy
12
33
32 (3-‐yr)
Fode
Retrospect
225
3x15-‐22.5
29
LR: 13
80, 58
Liver mets: Local control rates 80-‐100%